RxDoctor Payments Data

Parham Eftekhari, DO

Nephrology · Fort Lauderdale, FLNPI 1922285998

Payments from drug & device makers

$22,374in general payments, 2019–2025

Across 477 payments — averaging $46.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$11K
  • AstraZeneca$2K
  • Amgen$1K
  • Lilly USA, LLC$983
  • Travere Therapeutics, Inc.$736
  • Vifor Pharma, Inc.$711
  • plus $5K from 22 others

What the payments were for

  • Speaking & faculty fees$11,78553%
  • Travel & lodging$430%
  • Food & beverage$10,22346%
  • Education$3221%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,374 in reported general payments places this provider in the 80th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$213,004
Medicare patients
380
Services billed
2,153

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol137$118,172
KerendiaFinerenone72$62,694
LokelmaSodium Zirconium Cyclosilicate48$39,209
JardianceEmpagliflozin49$30,749
ProcritEpoetin Alfa24$16,526
VeltassaPatiromer Calcium Sorbitex15$15,123
Cinacalcet Hcl24$6,149
Nifedipine ErNifedipine103$3,917
Sevelamer Carbonate32$3,394
Clonidine22$3,104
Valsartan100$2,923
Labetalol Hcl32$1,617
Carvedilol154$1,163
Hydralazine Hcl49$982
Losartan Potassium157$982

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$2,404$157,381185 claims
BayerKerendia$414$62,69472 claims
Boehringer IngelheimJardiance$11,414$30,74949 claims
ANI Pharmaceuticals, Inc.Valsartan$278$2,923100 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 756 nephrology providers in Florida.

Other nephrology in Fort Lauderdale

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →